Pro-drug compounds

A compound according to formula (I) or a hydrate, solvate, or pharmaceutically acceptable salt thereof:

• wherein
• Z1, Z2, and Z3 are each independently selected from H, F, or Cl,
• Q is O,
• R2 is H,
• A is a direct bond, —C(O)O*—, C(R3)(R4)O*—, —C(O)NH* wherein the atom marked * is directly connected to R1,
• R3 and R4 are selected independently from H, fluoro, C1-4 alkyl, or C1-4 fluoroalkyl, or R3 and R4 together with the atom to which they are attached form a cyclopropyl group,
• R1 is selected from any one of the groups [1], [2], [3], [4], [5], [6], [7], [8], [9] or [10] wherein the atom marked ** is directly connected to A:
• n is 0, 1, 2, or 3,
• R5 is hydrogen,
• R6 is selected from —CH2CH(OH)CH2OH, or —CH2CH2R9,
• R7 and R7b are independently selected from H, C1-4 alkyl, or C1-4 fluoroalkyl,
• R8 and R8b are selected from:
• (i) H, C1-4 alkyl, or C1-4 fluoroalkyl, or
• (ii) the side chain of a natural or unnatural alpha-amino acid,
• or R7 and R8 together with the atom to which they are attached form a C3-7 carbocyclic ring,
• R9 is selected from —N(R11)(R12), or —N+ (R11)(R12)(R13)X−, N(R11)C(O)R14, —SO3H, or —OP(O)(OH)2,
• wherein R11, R12, and R13 are independently selected from H, C1-4 alkyl, or C1-4 fluoroalkyl, or
• R11 and R12 together with the nitrogen atom to which they are attached form a 4-7 membered heterocyclic ring optionally substituted with one or more groups selected from H, fluoro, C1-4 alkyl, C1-4 fluoroalkyl, C1-4 alkoxy, or —C(O)R3,
• or in the case where R1 is group [7], R9 is —NR11R12, wherein R11 is hydrogen, C1-4 alkyl, or C1-4 fluoroalkyl, and R12 is C1-4 alkyl, or C1-4 fluoroalkyl, and R12 joins together with R8b such that R12 and R8b together with the nitrogen to which R12 is attached form a 5 or 6 membered cyclic amine group,
• R14 is H, C1-4 alkyl, or C1-4 fluoroalkyl,
• X− is a pharmaceutically acceptable anion,
• R15 is 3-pyridyl or 1,4-dihydro-1-methyl-pyridin-3-yl,
• Y is —O—, —CH2—, —N(H)—, or —N(CH3)—.